share_log

Equities Analysts Set Expectations for Antibe Therapeutics Inc.'s FY2023 Earnings (OTCMKTS:ATBPF)

Defense World ·  Sep 13, 2022 01:41

Antibe Therapeutics Inc. (OTCMKTS:ATBPF – Get Rating) – Investment analysts at Zacks Small Cap increased their FY2023 EPS estimates for Antibe Therapeutics in a research note issued to investors on Wednesday, September 7th. Zacks Small Cap analyst D. Bautz now expects that the company will post earnings per share of ($0.35) for the year, up from their previous estimate of ($0.36). The consensus estimate for Antibe Therapeutics' current full-year earnings is ($0.31) per share.

Get Antibe Therapeutics alerts:

Separately, Brookline Capital Management reaffirmed a "buy" rating on shares of Antibe Therapeutics in a report on Thursday, June 30th.

Antibe Therapeutics Price Performance

Antibe Therapeutics stock opened at $0.49 on Monday. Antibe Therapeutics has a 1-year low of $0.42 and a 1-year high of $1.07. The company's 50-day moving average is $0.48 and its 200 day moving average is $0.53.

Antibe Therapeutics Company Profile

(Get Rating)

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.

Recommended Stories

  • Get a free copy of the StockNews.com research report on Antibe Therapeutics (ATBPF)
  • Darden Restaurants Takes the Low Road Against Inflation
  • Why These 3 Stocks Are Off to Hot September Starts
  • Inflation Doesn't Differentiate, But it's Impact Does
  • 3 Downgraded Must-Have Stocks To Put On Your Watchlist
  • This Is What To Expect From The Q3 Earnings Reporting Season

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment